Stock listing

Rocket Pharmaceuticals, Inc.

Selected listing: A2JA9Q · LS · EUR · DE

Rocket Pharmaceuticals, Inc. (Lang & Schwarz: A2JA9Q), Health Technology. Latest release Oct 6, 2026: Rocket Pharmaceuticals Secures Strategic Credit Facility…

A2JA9Q:LSEURDEUpdated September 25, 2026

Ticker: Lang & Schwarz: A2JA9Q
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

October 6, 2026

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

September 15, 2026

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

August 10, 2026

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

August 3, 2026

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026

All Rocket Pharmaceuticals, Inc. news →

Events

Replays

Rocket Pharmaceuticals, Inc. (RCKT) Q2 2021 Earnings Call
Mon, Aug 09, 2021 · 04:30 PM ET
Watch

Research Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. company profile

View the public company page for Rocket Pharmaceuticals, Inc. on 6ix.

Rocket Pharmaceuticals, Inc. news

Read company news and market updates connected to Rocket Pharmaceuticals, Inc..

Rocket Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Rocket Pharmaceuticals, Inc..